Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2022 08:00 ET | Source: TFF Pharmaceuticals, Inc.

TFF Pharmaceuticals Announces Collaboration with Aptar Pharma to Explore and Develop Intranasal Delivery of Dry Powder Vaccines and Dry Powder Therapeutics

Administration of dry powders will utilize Aptar Pharma’s Unidose (UDS) Powder Nasal Spray System The TFF dry powder vaccines maintain the antigen’s integrity, can be delivered to the targeted region...
November 01, 2022 16:07 ET | Source: TFF Pharmaceuticals, Inc.

TFF Pharmaceuticals Announces Second Patient Successfully Treated with Voriconazole Inhalation Powder Through Compassionate Use Program

Marks the Second Patient to Clinically Benefit from Administration of Voriconazole Inhalation Powder (TFF VORI) Using Thin Film Freezing-Based Technology Positive Results from First Patient Treated...
November 01, 2022 16:05 ET | Source: TFF Pharmaceuticals, Inc.

TFF Pharmaceuticals Announces Program Updates for Voriconazole Inhaled Powder and Tacrolimus Inhaled Powder Clinical Programs

FORT WORTH, Texas, Nov. 01, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
October 11, 2022 08:00 ET | Source: TFF Pharmaceuticals, Inc.

TFF Pharmaceuticals Announces Presentation of Data Featuring Applications of Thin Film Freezing Technology at AAPS PharmSci 360 Meeting

Two Presentations Featuring Thin Film Freezing Technology Selected for the Meeting’s Special Poster Collections Demonstrates Use of Thin Film Freezing to Produce Dry Powder Inhaled Formulations of...
September 26, 2022 08:00 ET | Source: TFF Pharmaceuticals, Inc.

TFF Pharmaceuticals to Participate in the Roth Inaugural Healthcare Opportunities Conference

FORT WORTH, Texas, Sept. 26, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
September 22, 2022 08:00 ET | Source: TFF Pharmaceuticals, Inc.

TFF Pharmaceuticals Announces Acceptance of Multiple Abstracts Featuring Applications of Thin Film Freezing Technology at the Upcoming AAPS PharmSci 360 Meeting

Two Abstracts Selected for Presentation as part of the Meeting’s Special Poster Collections Research Focuses on the Use of Thin Film Freezing to Produce Dry Powder Inhaled Formulations of...
September 08, 2022 08:00 ET | Source: TFF Pharmaceuticals, Inc.

TFF Pharmaceuticals Announces Presentation of Patient Data with Voriconazole Inhalation Powder (TFF VORI) at the 15th International Congress on Lung Transplantation

Dr. Bradley Gardiner from the Royal Alfred Hospital in Melbourne, Australia presented results from compassionate use of treating pulmonary fungal infections in a lung transplant patient Patient...
September 06, 2022 08:00 ET | Source: TFF Pharmaceuticals, Inc.

TFF Pharmaceuticals to Participate at The H.C. Wainwright 24th Annual Global Investment Conference

FORT WORTH, Texas, Sept. 06, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
August 11, 2022 16:05 ET | Source: TFF Pharmaceuticals, Inc.

TFF Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

Phase 2 Inhaled Voriconazole Powder and Inhaled Tacrolimus Powder Programs Continue to Advance Expands R&D Operations with New Austin, TX Facility Recent Feasibility Work Confirms...
August 02, 2022 16:05 ET | Source: TFF Pharmaceuticals, Inc.

TFF Pharmaceuticals to Hold Second Quarter 2022 Financial and Business Results Conference Call on August 11, 2022

FORT WORTH, Texas, Aug. 02, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right